Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 13/20 | 0.52 |
| ▸ | GIPR | P48546 | 4/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2655953 | 1.00 | GCGR (0.52) | GCGRGIPRTRPV1DHODHCYP3A4 | |
| SCHEMBL2665225 | 0.98 | GCGR (0.52) | GCGRGIPRTRPV1DHODHCYP3A4 | |
| SCHEMBL2647975 | 0.95 | GCGR (0.52) | GCGRGIPRTRPV1DHODHCYP3A4 | |
| SCHEMBL2647981 | 0.95 | GCGR (0.52) | GCGRGIPRTRPV1DHODHCYP3A4 | |
| SCHEMBL9071398 | 0.91 | GCGR (0.46) | GCGRGIPRTRPV1DHODH | |
| SCHEMBL9071397 | 0.90 | GCGR (0.46) | GCGRGIPRTRPV1DHODHCYP3A4 | |
| SCHEMBL2647920 | 0.88 | GCGR (0.53) | GCGRGIPRTRPV1CYP3A4CYP2C8 | |
| SCHEMBL2647916 | 0.88 | GCGR (0.53) | GCGRGIPRTRPV1CYP3A4CYP2C8 | |
| SCHEMBL2665228 | 0.86 | GCGR (0.44) | GCGRGIPR | |
| SCHEMBL2665222 | 0.85 | KMT2A (0.41) | GCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1463715-A1 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2004-10-06 | — | — | EP | disclosed |
| US-6762318-B2 | CARBOXYLIC ACID OR TETRAZOLE DERIVATIZED SECONDARY AMIDES; ORAL ADMINISTRATION | NOVO NORDISK A/S (DK) | 2004-07-13 | — | — | US | disclosed |
| US-20030236292-A1 | Stimulant releasing glucose from liver cells; antidiabetic agents | PFIZER INC | 2003-12-25 | — | — | US | disclosed |
| WO-2003048109-A1 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236292-A1 | Stimulant releasing glucose from liver cells; antidiabetic agents | GPR119, GLP1R, GIPR | GCGR 4/4885GIPR 3/4885TRPV1 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.